RxDoctor Payments Data

Brittany Hunter, APRN

Adult Health · Benton, KYNPI 1568740108

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 38.6% of the total. Reporting peaked in 2023 at $618 and has fallen 97.8% since, to $14 in 2025.

$1,641in general payments, 2019–2025

Across 104 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$634
  • Novo Nordisk$291
  • Lilly USA, LLC$75
  • Amarin Pharma, Inc.$68
  • Amgen$66
  • Boehringer Ingelheim$62
  • plus $444 from 14 others

What the payments were for

  • Food & beverage$1,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,641 in reported general payments places this provider in the 70th percentile of 170 adult health providers in Kentucky.

See all adult health providers in Kentucky

Medicare billing

Part B allowed, 2024
$52,505
Medicare patients
269
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol31$37,237
EliquisApixaban36$36,981
OzempicSemaglutide21$29,246
MounjaroTirzepatide27$28,004
JardianceEmpagliflozin22$20,024
TrulicityDulaglutide11$17,533
TrintellixVortioxetine Hydrobromide12$5,753
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen89$2,148
Gabapentin112$1,503
Albuterol Sulfate HfaAlbuterol Sulfate42$1,407
Memantine Hcl18$1,347
Diclofenac Sodium40$1,003
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm11$953
Cefdinir82$849
Omeprazole85$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$75$45,53738 claims
AstraZenecaFarxiga$33$37,23731 claims
Novo NordiskOzempic$291$29,24621 claims
Boehringer IngelheimJardiance$62$20,02422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 170 adult health providers in Kentucky.

Other adult health in Benton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →